ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2014
Use of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Directed evolution-driven reprogramming of PD-L1 for compact and tunable checkpoint modulation.Journal of biological engineering · 2025Article
- Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET.EJNMMI radiopharmacy and chemistry · 2024Article
- Functionalization of Radiolabeled Antibodies to Enhance Peripheral Clearance for High Contrast Brain Imaging.Molecular pharmaceutics · 2022Article
- Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Article
- The Neonatal Fc Receptor (FcRn): A Misnomer?Frontiers in immunology · 2019Review
- Targeting FcRn to Generate Antibody-Based Therapeutics.Trends in pharmacological sciences · 2018Review
- Targeting Phosphatidylserine with Calcium-Dependent Protein-Drug Conjugates for the Treatment of Cancer.Molecular cancer therapeutics · 2018Article
- Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Protein & cell · 2018Review
- Magnetic Particle Imaging: A Novel in Vivo Imaging Platform for Cancer Detection.Nano letters · 2017Article
- Article
- In vivo imaging with antibodies and engineered fragments.Molecular immunology · 2015Review
- Targeting FcRn for the modulation of antibody dynamics.Molecular immunology · 2015Review
- The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.Advanced drug delivery reviews · 2015Review
- Commentary: "There's been a Flaw in Our Thinking".Frontiers in immunology · 2015Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledDespite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo half-lives result in poor contrast and radiation damage to normal tissue. This study describes an approach to overcome these limitations.
methodsMice bearing human epidermal growth factor receptor type 2 (HER2)-overexpressing tumors were injected with radiolabeled ((124)I, (125)I) HER2-specific antibody (pertuzumab). Pertuzumab injection was followed 8 h later by the delivery of an engineered, antibody-based inhibitor of the receptor, FcRn. Biodistribution analyses and PET were performed at 24 and 48 h after pertuzumab injection.
resultsThe delivery of the engineered, antibody-based FcRn inhibitor (or Abdeg, for antibody that enhances IgG degradation) results in improved tumor-to-blood ratios, reduced systemic exposure to radiolabel, and increased contrast during PET.
conclusionAbdegs have considerable potential as agents to stringently regulate antibody dynamics in vivo, resulting in increased contrast during molecular imaging with PET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.